Initial experience of prostatic urethral lift (UroLift); A minimally invasive treatment for symptomatic benign prostatic hyperplasia  by Hulligan, S. et al.
Abstracts / International Journal of Surgery 36 (2016) S31eS132S126patients. 73% of these GPs had received no formal training on the man-
agement of such patients.
Conclusion: The repatriation of men with stable prostate cancer is largely
preferred by patients. There is a need for greater patient and GP education
with clear protocols available to give conﬁdence to all parties in follow-up
care.http://dx.doi.org/10.1016/j.ijsu.2016.08.467
0715: VISIBE HAEMATURIA DUE TO UTI e DOES IT NEED
INVESTIGATING?
B. Starmer*, A. Singh, S. Bromage. Stockport NHS Foundation Trust, Stockport,
UK.
Aim: It is well documented that UTI can cause visible haematuria (VH).
Current NICE guidelines suggest that VH secondary to UTI does not need
investigating. While this is intuitive, it is not based on any evidence. We
aim to establish any evidence towards or against this approach.
Method: Retrospective review of casenotes.
Result: There were 599 patients with VH. 299/599 had a negative urinal-
ysis for blood on the day of haematuria clinic. 302/599 had a recorded
MC+S in the 6 weeks prior to ﬂexible cystoscopy. 63/302 patients had a
positive culture on MC+S. 1/63 patient in this group was shown to have a
T1b left renal cell carcinoma. This patient had a positive dipstick on the day
of their haematuria clinic. No bladder tumours were found. 0/29 of those
who had a positive MC+S followed by a negative urinalysis on the day of
haematuria clinic were found to have cancer.
Conclusion: Here, we provide evidence that UTI with VH that has been
treated and has negative urinalysis following this requires no haematuria
investigations. We still advise that persisting non-visible haematuria
following treatment for UTI is investigatedhttp://dx.doi.org/10.1016/j.ijsu.2016.08.468
0793: VENOUS THROMBOEMBOLISM RISK SCORES IN UROLOGICAL PA-
TIENTS: A COMPARISON OF DIFFERENT SCORING METHODS
M. Karia*, S. Onida, A. Davies. Imperial College London, London, UK.
Aim: 1-5% of patients undergoing major urological surgery experience
symptomatic venous thromboembolism (VTE), with pulmonary embolism
(PE) the most common cause of post-operative death. The Caprini and
Department of Health (DoH) scores are assessment systems estimating
VTE risk and the requirement for pharmacological thromboprophylaxis.
The aim of this study was to assess the agreement between these two
assessment methods in urology patients.
Method: 78 patients undergoing urological procedures were prospectively
risk assessed using the Caprini and DoH VTE score and categorized into
low, medium or high risk. Inter-rater agreement was assessed using
Cohen's Kappa coefﬁcient.
Result: There was a 73% agreement between the two scoring methods.
Cohen's kappa coefﬁcient was 0.571 indicating ‘moderate agreement'. Of
the 21 patients where therewas a disagreement, 6 were categorized as low
risk according to one score (3 DoH, 3 Caprini) and medium risk according
to the second score.
Conclusion: We demonstrate a ‘moderate agreement' between scoring
methods in urological patients. The disagreement between low/medium
scoring is clinically relevant, as these patients would have only been pre-
scribed pharmacological thromboprophylaxis depending on the scoring
system used. Further research efforts are required to assess the impact of
differences in these scoring systems in this patient cohort.http://dx.doi.org/10.1016/j.ijsu.2016.08.469
0842: PROSTATIC MEMOKATHS. A LONG-TERM FOLLOW UP OF 35
CASES
C. Mosli-Lynch, N. Chari, L. Forster, C. Tanabalan, P. Patki. St Bartholomew's
Hospital, LONDON, UK.Objective: To examine the long-term efﬁcacy of an expanding metallic
stent (Memokath) placed in patients with obstruction of the prostatic
urethra who were unﬁt or unsuitable for surgical intervention, in order to
determine a population of patients in whom a prostatic memokath would
be a suitable treatment.
Method: We followed up 35 patients who had a prostatic Memokath
placed in a single unit between 2005 and 2009 to assess their long-term
functional outcome. Aside from demographic factors and reason for
insertion we looked at migration rate, replacement rate and survival
times.
Result: Themean age at insertionwas 78.13 patients are still alive with the
Memokath in situ (mean time 86.3 months). 9 patients died with the
Memokath in situ, mean survival time: 29.3months (range 1-69). In eleven
patients the Memokath either migrated (5) or was removed (6) with a
mean time of 3.7 months (range 5 days- 11 months). Two patients were
lost to follow up.
Conclusion: Prostatic Memokaths are useful in patients who are unable to
tolerate either a GA or a LASER resection of the prostate, and who have a
reasonable life expectancy. Though a proportion either migrate or neces-
sitate removal, the majority are well tolerated.http://dx.doi.org/10.1016/j.ijsu.2016.08.470
0930: INITIAL EXPERIENCE OF PROSTATIC URETHRAL LIFT (UROLIFT); A
MINIMALLY INVASIVE TREATMENT FOR SYMPTOMATIC BENIGN PROS-
TATIC HYPERPLASIA
S. Hulligan*, E. Johnson, R. Mistry, H. Gana. Whiston Hospital, Merseyside,
UK.
Introduction: The UroLift procedure in treating LUTS secondary to BPH
has recently been accredited by NICE (September-2015) for men over
50years, with prostates under 100ml without an obstructing middle
lobe. The system avoids the risk to sexual function associated with
current gold standard of TURP, & HoLEP. Initial outcome experience of
Urolift.
Method: Patients assessed both prospectively and retrospectively. Vari-
ables analysed included; pre/post-procedure IPSS, QoL, erectile and ejac-
ulation function. Patients were assessed periodically post-procedure to
evaluate initial outcomes.
Result: 13 Urolift procedures analysed. Mean 65years(range 58-77), all
failed medical management(13). Prostates size 25g-85g, mean PSA 1.66ug/
l. Pre-procedure Qmax mean 13.86ml/sec. All were day-case procedures,
no post-procedure urinary retention, no signiﬁcant adverse effects.
During 1-8months follow up; IPSS mean improved; 20.1(7-31) pre-pro-
cedure to 6.5(1-16) post-procedure(67.7%symptom reduction). QoL score
improved 4.3(2-6)to 1.4(1-6). No QoL improvement in one patient, one
patient 4month delayed improvement due to persistent storage
symptoms.
Post-procedure zero patients experienced retrograde ejaculation. Zero
experienced new erectile dysfunction(ED). 6 had ED prior, zero reporting
deterioration, two reporting improvement.
Conclusion: Urolift is a safe, efﬁcacious treatment of BPH LUTs in the short
term, with a reduction in length of hospital stay. Longer term data will
follow. Preservation of tissue structures ensures sustained sexual function.http://dx.doi.org/10.1016/j.ijsu.2016.08.471
0953: REDUCING THE RISK OF BOWEL INJURY IN OUR NURSE-LED
OUTPATIENT SUPRAPUBIC CATHETER CLINIC
E. Papworth*, R. MacDonagh, A. MacCormick, R. Bamford. Musgrove Park
Hospital, Taunton, UK.
Aim: Rarely, suprapubic catheter insertion is associated with the risk of
bowel perforation. We assessed risk of bowel injury both before and after
the introduction of ultrasound scanning (USS) as an adjunct to SPC
insertion.
Method: A dedicated SPC clinic was established in July 2008, undertaken
by a formally structurally trained specialist nurse.
